2035 Inc. and QLasers: Hand-Pain Clearance, Claims to Treat Cancer

The 2035 Inc. QLasers injunction stopped the company and its owner from manufacturing and distributing medical devices until they met the court’s conditions, and ordered the owner to refund buyers. The business sold lasers with claims about treating cancer, HIV/AIDS and diabetes. The cleared use was temporary relief of hand pain from osteoarthritis.

The Justice Department’s account of the permanent injunction describes findings after trial. The government established that the labeling was false and misleading and that following the devices’ directions could be dangerous to health.

What Were the QLaser Devices Cleared to Treat?

Two QLaser devices had Food and Drug Administration clearance for temporary relief of pain associated with osteoarthritis of the hand. According to the Justice Department, none had clearance or approval to treat other medical conditions. Yet the court found that the owner and his businesses marketed and distributed the devices nationwide for more than 200 diseases and medical disorders.

Consumers facing serious illness were offered far more than the devices had been authorized to do. The Justice Department reported that using the lasers to treat other serious conditions had no support in published clinical studies.

The labeling reached well beyond the hand-pain use that had been cleared.

Private Membership Was Part of the Sales Process

The owner solicited purchasers to join private membership associations before buying the lasers. QLasers PMA and 2035 PMA were among the business names through which he marketed them.

The Justice Department’s preliminary-injunction announcement reported the court’s rejection of the claim that those associations shielded the owner from federal device law or the court’s authority. Calling the transaction private did not change the treatment claims attached to the lasers.

The preliminary order also reached business affiliates and franchisees. Membership associations had been used to sell the devices across the country, but the court’s manufacturing and distribution restrictions reached beyond the company to that sales network.

From the Government’s Complaint to Findings at Trial

The Justice Department brought the civil action in October 2014 under the Food, Drug, and Cosmetic Act. Its complaint alleged nationwide marketing of the lasers for unauthorized treatment uses.

In January 2015, a preliminary injunction barred further manufacturing and distribution while the government pursued a permanent order. The court found that the owner and his businesses had shown no intent to stop their activities voluntarily. Continued marketing and distribution required written permission from the Food and Drug Administration.

The trial followed in March, and the court entered the permanent injunction in October 2015. The case had moved from the government’s allegations to findings that the company misled consumers and that following its directions could endanger their health.

The Permanent Injunction Reached the Whole Operation

The permanent injunction required the owner and his businesses to stop directly or indirectly manufacturing, packing, labeling or distributing any medical device until they complied with the order’s conditions.

The Food and Drug Administration said the businesses had ignored its previous warnings and continued producing and distributing the devices. The order reached the packing and labeling that carried the treatment claims to customers, as well as the manufacture and sale of the lasers themselves.

The order also carried a financial consequence for continued noncompliance. The order requires the owner to pay the United States $10,000 a day for any violation of the injunction.

The Owner’s Personal Responsibility and Buyer Refunds

The owner operated 2035 Inc. and marketed the lasers through the membership associations. The court bound him personally as well as his businesses. Its refund requirement specifically directed him to return the full amount consumers had paid, including purchases made through distributors.

The evidence before the court put the typical package price between $4,295 and $12,600. The owner admitted selling at least 20,000 devices since 1998. These were substantial purchases backed by claims about treating serious illness, and the court ordered the money returned to the people who made them.

The Buyer Payment and the Government Claim

The QLasers action enforced federal device law and ordered refunds to consumers. In the Vascular Solutions case, the whistleblower alleged that representatives were instructed to recommend treating individual veins on separate days to maximize provider reimbursement because additional veins treated on the same day drew a lower rate than the first vein.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

You Know What Customers Were Told

If you saw a device sold on treatment claims that outran its clearance, speak with our whistleblower experts about the promises and payments behind those sales. We build the case with you, bring in medical-device fraud whistleblower lawyers who understand product promotion and government reimbursement, and stay beside you through its pursuit.